Price
No data yet.
Social Signal Score
Analyst Ratings
13 analystsRevenue
$100.92M+16.66%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Stephen R. LaNeve
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 809
- Beta
- 1.39
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -0.68
Financials
Revenue
$100.92M+16.7%Net Income
$-1.94MEBITDA
$71.0KFree Cash Flow
$1.97MEPS (diluted)
$-0.02Shares Outstanding (diluted)
122.64M+50.3%Operating Expenses
$26.46MCash & Debt
$40.62MReturn of Capital
$0.00Revenue by Segment (annual)
$401.95MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $401.95M | $-49.19M | $-0.40 |
| 2025 | $458.50M | $-1.59M | $-0.02 |
| 2024 | $446.55M | $-15.54M | $-0.16 |
| 2023 | $447.61M | $-9.28M | $-0.10 |
| 2022 | $429.91M | $-5.35M | $-0.06 |
| 2021 | $396.29M | $-6.31M | $-0.07 |
| 2020 | $382.93M | $3.83M | $0.04 |
| 2019 | $418.79M | $-16.43M | $-0.19 |
| 2018 | $404.90M | $-23.90M | $-0.28 |
| 2017 | $383.41M | $-29.58M | $-0.36 |
| 2016 | $398.80M | $-25.50M | $-0.32 |
| 2015 | $379.80M | $-40.21M | $-0.51 |
| 2014 | $369.42M | $-35.45M | $-0.47 |
| 2013 | $315.97M | $-103.22M | $-1.41 |
Valuation
ARAYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (5)
- Newsprnewswire.com·8d ago·Negative
Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife® Platform MADISON, Wis., Sept. 27, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced that it had entered into agreements with Samsung HME America, Inc., dba NeuroLogica Corp. ("Samsung NeuroLogica") to pursue advanced volumetric imaging capabilities for the CyberKnife® System.
View source ↗ - Newsprnewswire.com·24d ago·Negative
…tion Software with Accuray Platforms to Accelerate Accuray's Online Adaptive Capabilities MADISON, Wis., Sept. 11, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, and RaySearch Laboratories AB (publ) today announced that they had entered into a definitive agreement providing for an expanded collaboration aimed at accelerating Accuray's adoption of online adaptive radiation therapy.
View source ↗ - Newsseekingalpha.com·47d ago·Positive
Accuray Incorporated (ARAY) Q4 2026 Earnings Call Transcript Accuray Incorporated (ARAY) Q4 2026 Earnings Call Transcript
View source ↗ - Newsprnewswire.com·47d ago·Neutral
Accuray Reports Fourth Quarter and Fiscal 2026 Financial Results MADISON, Wis., Aug. 19, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2026, ended June 30, 2026.
View source ↗ - Newsprnewswire.com·54d ago·Neutral
Accuray Advances Strategic Priorities Through Key Executive Leadership Appointments MADISON, Wis., Aug. 12, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced two key leadership appointments intended to improve operational execution and profitability, deliver increased customer value, and enhance overall enterprise performance as the company continues to advance the strategic priorities in its recently announced transformation plan focused on sustainable, profitable growth.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.07 per share
Typical surprise -2.2% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 19$-0.02 vs $-0.03beat
- Wed, May 6$-0.09 vs $-0.05miss
- Wed, Feb 4$-0.11 vs $-0.11miss
- Wed, Nov 5$-0.18 vs $-0.01miss
- Wed, Aug 13$0.01 vs $0.03miss
- Wed, Apr 30$-0.01 vs $-0.05beat
Estimates and results for ARAY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ARAY officers and directors.
- Bought
- $216k
- Sold
- —
5 trades
0 trades
- Mayer Steven Fbought
- Mayer Steven Fbought
- Mayer Steven Fbought
- La Neve Stephen R.bought
- Whitters Joseph Ebought
95 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ARAY.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.